Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

State Roundup: Budget cuts in Texas, Wash. State; Ariz. smoking, weight fees; Coping with Rx drug abuse

The Texas House voted 98-49 Sunday night to slash funding for public schools, nursing homes and college financial aid in a dramatic show by Republicans elected on a limited-government message in the face of a massive budget shortfall.

4 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.

4 Apr 2011

OncoSec acquires certain assets of Inovio

OncoSec Medical Incorporated, a developer of innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today that on March 24, 2011 it completed its acquisition of certain assets of Inovio Pharmaceuticals, Inc. and entered into a license agreement with Inovio, pursuant to the terms of an asset purchase agreement with Inovio entered into on March 14, 2011.

4 Apr 2011

Experts to discuss on healthcare-associated infection at SHEA Annual Meeting

A special media phone briefing with leading infectious disease scientists and healthcare-associated infection experts who will headline the 2011 Society for Healthcare Epidemiology of America's Annual Meeting

4 Apr 2011

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

Bristol-Myers Squibb Company today announced results from the Phase IIb EMERGE clinical trial, in which treatment with the investigational compound PEG-Interferon lambda and ribavirin achieved higher rates of rapid virologic response in genotypes 1, 2, 3, and 4, and complete early virologic response in genotypes 1 and 4 than the standard regimen of PEG-Interferon alfa and ribavirin in treatment-naïve patients chronically infected with hepatitis C.

4 Apr 2011

New data finds PegIFN-lambda shows RVR in HCV patients with improved safety, tolerability

Highly exciting new data presented today at the International Liver Congress found Pegylated Interferon-lambda shows superior virological response in HCV patients of genotypes 1-4, with improved safety and tolerability, compared to Pegylated Interferon-alpha, the current standard of care in chronic HCV.

4 Apr 2011

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.

2 Apr 2011

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve patients chronically infected with hepatitis C virus genotype 1.

2 Apr 2011

Transgenomic to present study results of high-sensitivity cancer mutation assays at AACR

Transgenomic, Inc. announced today that its scientists have completed studies employing the company's high-sensitivity cancer mutation assays using two proprietary technologies, Ice COLD-PCR and BLOCker-Sequencing. Results from these studies will be presented at the American Association for Cancer Research meeting in Orlando, Florida, April 2-6, 2011.

2 Apr 2011

Sinai Hospital offers new program that can help improve pediatric patients' lung function

Better breathing through playing the harmonica is a new program used at Sinai Hospital in Baltimore, Maryland, to help pediatric patients with asthma and pneumonia and pediatric patients who are postoperative to exercise their lungs.

1 Apr 2011

Geisinger expert offers advice on how to manage child's asthma

Asthma is the leading cause of hospital visits and missed school days in children, according to the National Institute of Health. A chronic condition, pediatric asthma requires continual care to prevent serious, life-threatening asthma attacks.

1 Apr 2011

Pediatrician suggests tips to combat allergic symptoms

One of the problems that parents may have during the springtime is deciphering whether their children's sneezing is due to a cold or allergies.

1 Apr 2011

Research roundup: Patient's income and electronic health records; high deductible plans; raising Medicare age

Healthcare Spending And Preventive Care In High-Deductible And Consumer-Directed Health Plans - Authors analyzed data from more than 800,000 families insured during 2004 and 2005 through one of 53 large employers in U.S., about half offering the high-deductible or consumer-directed plans.

1 Apr 2011

Biota receives US$231 million BARDA contract to advance laninamivir development

Biota Holdings Limited advises that the Office of Biomedical Advanced Research and Development Authority within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services has awarded up to an estimated US$231 million contract to its wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of laninamivir.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

New research sheds light on Sudden Infant Death Syndrome

New research published today in The Journal of Physiology sheds light on areas of the brain thought to be the root cause of Sudden Infant Death Syndrome - the poorly understood condition also known as 'cot death'.

1 Apr 2011

Study: Electronic faucets more likely to become contaminated with bacteria

Researchers at The Johns Hopkins University School of Medicine have determined that electronic faucets are more likely to become contaminated with unacceptably high levels of bacteria, including Legionella spp., compared with traditional manually operated faucets.

1 Apr 2011

Biota Scientific receives BARDA contract to develop single-dose antiviral drug

A contract has been awarded to develop a long-acting single-dose antiviral drug for use in the United States, the U.S. Biomedical Advanced Research and Development Authority announced today.

1 Apr 2011

Hands-free electronic water faucets more likely to be contaminated with hazardous bacteria

A study of newly installed, hands-free faucets at The Johns Hopkins Hospital, all equipped with the latest electronic-eye sensors to automatically detect hands and dispense preset amounts of water, shows they were more likely to be contaminated with one of the most common and hazardous bacteria in hospitals compared to old-style fixtures with separate handles for hot and cold water.

1 Apr 2011

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

State Roundup: Budget cuts in Texas, Wash. State; Ariz. smoking, weight fees; Coping with Rx drug abuse

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

OncoSec acquires certain assets of Inovio

Experts to discuss on healthcare-associated infection at SHEA Annual Meeting

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

New data finds PegIFN-lambda shows RVR in HCV patients with improved safety, tolerability

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Transgenomic to present study results of high-sensitivity cancer mutation assays at AACR

Sinai Hospital offers new program that can help improve pediatric patients' lung function

Geisinger expert offers advice on how to manage child's asthma

Pediatrician suggests tips to combat allergic symptoms

Research roundup: Patient's income and electronic health records; high deductible plans; raising Medicare age

Biota receives US$231 million BARDA contract to advance laninamivir development

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

New research sheds light on Sudden Infant Death Syndrome

Study: Electronic faucets more likely to become contaminated with bacteria

Biota Scientific receives BARDA contract to develop single-dose antiviral drug

Hands-free electronic water faucets more likely to be contaminated with hazardous bacteria

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in